Skip to main content

Table 1 Demographic and PID features of 28 children receiving weekly (Q1W) or biweekly (Q2W) Hizentra® treatment

From: Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data

  SHIFT, Q1W (N = 15) IBIS, Q2W (N = 13) Difference (90% CI)a Overall (SHIFT-IBIS) (N = 28)
Gender (male) 11 (74.3%) 10 (76.9%) RR = 1.05 (0.73–1.51) 21 (75.0%)
Age (years) 11.9 ± 4.6 (13; 11–15) 11.5 ± 4.1 (13; 9–14) Δ = − 0.33 (− 2.99 to 2.33) 11.7 ± 4.3 (13; 10–15)
Height (cm) 148.4 ± 27.8 (157; 138–167) 148.5 ± 24.7 (159; 138–165) Δ = 0.03 (− 15.97 to 16.02) 148.4 ± 25.9 (158; 136–166)
Weight (kg) 50.3 ± 22.6 (55; 33–63) 47.4 ± 19.8 (47; 34–61) Δ = − 2.85 (− 15.77 to 10.06) 48.9 ± 21 (49; 33–62)
BMI (kg/m2) 21.4 ± 4.7 (23; 17–24) 20.5 ± 4.9 (19; 18–24) Δ = − 0.82 (− 3.75 to 2.11) 21 ± 4.7 (20; 17–24)
Serum IgG trough levels before Hizentra® use (g/L) 8.2 ± 1.1 (8.3; 7–9) 8.6 ± 2.6 (7.7; 7–10) Δ = 0.40 (− 1.29 to 2.08) 8.3 ± 1.6 (8.1; 7–9)
  1. Data are reported as the mean ± standard deviation (median; interquartile range) except for the male gender, which is reported as the number of subjects (percentage)
  2. BMI body mass index, CI confidence interval, Δ absolute difference, Q1W weekly administration, Q2W biweekly administration, RR risk ratio
  3. aMinimum p-value 0.645